The approach, called R-Evolution, or Rhinofiller Evolution, divides nonsurgical rhinoplasty into three planned treatment-and-assessment sessions spaced approximately 20 days apart. The first session provides the primary correction. At the second and third visits, the clinician reassesses nasal proportions, residual asymmetry, tissue response and whether further filler is clinically indicated; no additional product is injected if the result is already considered satisfactory. The staged schedule was intended to allow post-treatment edema to subside and the initial result to stabilize before further volume was considered, supporting conservative volume titration and limiting the potential for overcorrection.

Patients in the cohort were treated between 2022 and 2024. Their mean age was 29.6 years, and 89.8% were women. The investigators excluded people with severe nasal deviations, marked dorsal humps requiring surgical correction, severe structural deformities, significant functional nasal obstruction or aesthetic concerns considered better suited to conventional rhinoplasty. Other exclusion criteria included previous nasal surgery or filler treatment, pregnancy or breastfeeding, connective tissue disorders, bleeding disorders, allergy to lidocaine or hyaluronic acid, and a diagnosis or suspicion of body dysmorphic disorder. All procedures were performed by one plastic surgeon with 10 years of experience in facial injectable treatments, including nonsurgical rhinoplasty. Because the study took place in one private practice and involved a single experienced operator, its findings may not generalize to clinicians with different training or experience.

R-Evolution uses two crosslinked hyaluronic acid fillers, ART FILLER Universal and ART FILLER Volume, each containing 25 mg/mL hyaluronic acid and 0.3% lidocaine. ART FILLER Universal has a moderate elastic modulus, or G′, and was selected for smoothing and contouring, while ART FILLER Volume has a higher G′ and was selected for stronger structural support and projection. The authors also describe tan delta as the ratio of viscous to elastic behavior, with lower values indicating a more elastic gel associated with shape retention and structural support. The two products were used to combine contour refinement with support. The protocol did not introduce new injection sites; instead, it combined established anatomical targets with progressive reassessment, individualized volume distribution and the selective use of fillers suited to either contouring or structural support.

The injection sequence ran from superior to inferior through the nasion, nasal dorsum, columellar base, nasal tip and selected areas of septal deviation. A 30-gauge needle was used for contouring injections, while a 27-gauge needle was used for volumetric support. The nasion received 0.2 to 0.4 mL in avascular connective tissue; deep supraperiosteal injections addressed sagittal defects along the dorsum; no more than 0.2 mL was placed at the columellar base to enhance tip projection; and the nasal tip was treated at the midpoint between the domes. Deep injections over cartilage or bone could be used for septal deviations. The maximum cumulative injected volume per patient was 1.2 mL. Up to 0.8 mL could be administered during the first session, with a maximum additional 0.4 mL distributed across the second and third sessions if clinically indicated.

To reduce the chance of compromising blood flow, the operator injected slowly in tiny aliquots, used low extrusion pressure and intermittently released pressure after each push. Slight needle repositioning between aliquots was intended to avoid a large bolus in one location, while injections remained in deep planes where appropriate. Hyaluronidase was always available at the clinic, and patients were monitored for early signs of vascular compromise. If vascular occlusion was suspected, the protocol called for interruption of treatment and immediate management under established emergency procedures. The nasal region nevertheless has complex vascular anatomy and connections to the ophthalmic circulation. The discussion notes that severe complications including skin necrosis and blindness have been reported with filler injections, even though no major vascular complications occurred in this cohort. The reported absence of such events therefore applies only to the 137-person sample, the protocol used, the operator and the monitoring methods.

Among the 130 patients who completed the minimum three-month follow-up, 92, or 70.8%, were very satisfied and 34, or 26.2%, were satisfied with the aesthetic outcome. Four patients, representing 3.1% of the follow-up cohort, reported dissatisfaction and subsequently underwent treatment with hyaluronidase. None of those reversals was performed because of suspected vascular compromise. Seven of the original 137 patients did not attend the scheduled three-month assessment and were considered lost to follow-up; their reasons for nonattendance were not documented. The staged treatment pattern varied: 42 patients, or 32.3%, received no additional filler after the initial treatment, 32, or 24.6%, received additional filler during the second session only, and 56, or 43.1%, received additional filler during both the second and third sessions. The investigators classified these later injections as planned refinements within the protocol rather than retreatments for complications.

Adverse events were assessed immediately after each treatment session, during the second and third scheduled treatment-and-assessment visits, at the three-month follow-up and at any later available follow-up. Patients were told to contact the clinic and attend an unscheduled assessment if concerning symptoms developed between scheduled visits. Events were identified through clinical examination and patient reporting and were recorded in medical records. Monitoring covered edema, erythema, bruising, pain, tenderness, nodules, infection, asymmetry requiring correction and signs of vascular compromise, including blanching, livedoid discoloration, delayed capillary refill, skin necrosis and visual symptoms. Mild, self-limiting edema occurred in 41 patients, while 11 experienced minor bruising that resolved with conservative management. Four patients had moderate adverse events: one case of localized folliculitis and three episodes of delayed edema during systemic infections. All were successfully treated with medical therapy. No major vascular complications were observed, but the study was not large enough to characterize rare vascular emergencies.

Longer follow-up was available for a subset of the cohort: 96 patients reached 12 months, 41 reached 18 months and 18 reached 24 months. The researchers noted that satisfactory aesthetic results were often maintained beyond a year among patients for whom longer follow-up was available. However, follow-up duration was heterogeneous, and no objective measurements of durability were performed, so the study cannot establish how long the effects reliably persist. Other important limitations included the retrospective, single-center design, the absence of a control group, satisfaction ratings obtained retrospectively from routine records, and the lack of blinded or independent aesthetic evaluation. Although the operator considered the naso-frontal, naso-labial and naso-facial angles during planning, no formal angular measurements or digital analysis were performed. Standardized frontal and lateral photographs were obtained with the same smartphone under consistent lighting and positioning, but background conditions were not fully controlled. The results are preliminary and specific to the selected cohort, treatment protocol and experienced operator; prospective, controlled, multicenter studies with standardized photography, objective anthropometric measurements, validated patient-reported outcomes and blinded independent evaluators are needed to assess the approach more reliably.

Subject of Research: Evaluation of a staged hyaluronic acid filler protocol for nonsurgical rhinoplasty

Article Title: The “R-evolution” technique: a pilot observational study of a stepwise nonsurgical rhinoplasty approach using hyaluronic acid fillers

Article References: Castellaneta, F., Bianco, N., Lombardi, M., & D’Antonio, S. (2026). The “R-evolution” technique: a pilot observational study of a stepwise nonsurgical rhinoplasty approach using hyaluronic acid fillers. BMC Plastic and Reconstructive Surgery, 2(1), 29. https://doi.org/10.1186/s44452-026-00042-8

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00042-8

Keywords: nonsurgical rhinoplasty, hyaluronic acid fillers, R-Evolution technique, aesthetic medicine, patient satisfaction, observational study, filler complications, nasal reshaping, retrospective cohort, R-evolution, technique, pilot

The research team, led by Katerina Green and Deanna Menapace of the Department of Otolaryngology-Head and Neck Surgery, together with colleagues from dermatology and the Mayo Clinic Alix School of Medicine, conducted a systematic PubMed search that identified 19 published studies documenting adverse events associated with regenerative therapeutics in facial plastic surgery. They supplemented this literature analysis with a retrospective chart review of six patients treated at their own institution who experienced complications from these procedures. Their findings paint a detailed picture of what can go wrong when biologically active materials are injected into the highly vascular landscape of the face.

The technical appeal of these therapies is easy to understand. Platelet-rich plasma, or PRP, is derived from a patient’s own blood, which is centrifuged to concentrate platelets and the growth factors they carry. When injected into the skin or scalp, these factors stimulate angiogenesis and collagen synthesis, promoting tissue repair and regeneration. Nanofat, meanwhile, is produced by mechanically emulsifying harvested fat until mature adipocytes are broken down, leaving behind the stromal vascular fraction and adipose-derived stem cells with regenerative properties. Exosomes, tiny extracellular vesicles packed with signaling molecules, represent the newest frontier, marketed for anti-inflammatory and collagen-stimulating effects on skin texture and pore size.

Yet the review reveals that the most devastating complications share a common mechanism: vascular embolism. When injectable material enters an artery, it can travel retrograde into the ophthalmic artery and its branches, occluding blood supply to the retina or brain. The literature documents eight cases of vision loss following PRP injection, six of them permanent. Seven of these occurred after injections into the glabella, the region between the eyebrows where the supratrochlear and supraorbital arteries lie in close proximity to the ophthalmic system. Patients reported losing vision almost immediately, and central retinal artery occlusion is treatable only within an approximately four-hour window, a deadline frequently missed when injections occur in non-hospital settings.

Autologous fat grafting carries even greater documented risk. A systematic review cited in the paper identified 61 cases of arterial embolism after facial fat injection, including six deaths. In one reported case, an 18-year-old woman developed hemiplegia and loss of consciousness 24 hours after temporal fat injection; imaging revealed an infarction of the right external carotid artery caused by fat embolism, and despite decompressive craniotomy she died of central respiratory failure. In another, fat injected into the nasolabial fold entered the dorsal nasal artery and migrated to the ophthalmic artery, causing irreversible blindness. By contrast, nanofat injections appear far gentler: a review of 36 patients treated for periorbital dark circles found only transient bruising and mild edema, both resolving within days.

The Mayo Clinic cases add valuable new detail to this risk map. The first describes a 47-year-old woman who developed painful reactive lymphadenopathy the night after scalp PRP injections for hair loss, requiring emergency evaluation, CT imaging, and antibiotics before symptoms resolved. The authors suggest this may establish PRP alone, independent of microneedling with which it has previously been combined, as a trigger for lymph node swelling, possibly through local trauma or reaction to concentrated growth factors. The second case is the first of its kind: a 51-year-old woman developed facial tingling, numbness, and arm heaviness minutes after scalp PRP, prompting a full stroke workup. When imaging excluded ischemia, clinicians concluded she had experienced an acephalgic migraine with aura triggered by the procedure, a side effect never previously associated with PRP that may be relevant when injections follow trigeminal nerve distributions.

Three further institutional cases involved fat and nanofat. One patient who received temporal microfat and nanofat mixed with PRP developed delayed fat necrosis seven months after surgery, with a fluid collection that required serial aspiration and MRI confirmation, ultimately leaving the aesthetic result suboptimal. Two other patients developed nodular swelling after periorbital nanofat grafting; in one, intralesional triamcinolone resolved the nodules, while in the other persistent fullness required surgical excision, illustrating that treatment responses vary and clinical flexibility is essential. A sixth patient, treated with a topical human-derived exosome product after laser resurfacing, developed facial swelling and blistering consistent with suspected contact dermatitis, believed to be the first reported complication of topical exosome therapy in the United States.

The exosome literature emerging internationally is more concerning. Injectable exosome products are not approved by the US Food and Drug Administration, and their composition varies enormously between manufacturers depending on source material, isolation methods, and processing. Reported complications include granuloma formation, hypersensitivity reactions, persistent nodular lesions refractory to corticosteroids, and painful cutaneous necrosis that responded poorly even to carbon dioxide laser treatment. Notably, many of the severe reactions occurred after injections administered at private, non-hospital clinics, whereas a hospital-based retrospective series of 40 patients receiving exosome skin boosters with microneedling reported only expected erythema and edema resolving within 48 hours.

The authors emphasize that an underappreciated contributor to these complications is the profound heterogeneity of the products themselves. PRP preparation protocols differ in centrifugation speed, duration, and technique, producing wide variation in platelet concentration and cellular composition. Nanofat quality depends on harvesting location, instrumentation, and the number of emulsification passes. Exosome formulations differ in origin and purity. This variability limits reproducibility across studies and clinics, complicates comparisons of safety data, and means that two patients receiving nominally identical treatments may receive biologically distinct products. Regulatory frameworks have struggled to keep pace: the FDA regulates only minimally manipulated, homologous-use human cell products under 21 CFR 1271, PRP largely escapes the HCT/P framework as an autologous blood product, and recent state legislation such as a 2025 Florida law has expanded physician discretion to offer certain non-FDA-approved regenerative therapies.

Prevention, the authors argue, remains the most effective strategy because treatments for established embolic complications are notoriously unreliable. Ocular massage, anterior chamber paracentesis, intraocular pressure-lowering agents, hyaluronidase, hyperbaric oxygen, and intra-arterial thrombolysis have all been attempted for injection-related blindness, and none has proven consistently effective. Recommended safeguards include mapping vascular anatomy before procedures, avoiding bolus injections and previously traumatized sites, using small cannulas with low injection pressure and volume, employing ultrasound guidance where available, and maintaining an emergency protocol for immediate injection cessation with rapid referral to ophthalmology or emergency services. The researchers also call for candid discussion of risks in the literature, noting that favorable safety profiles and underreporting have combined to leave patients and providers underinformed. Their central message is measured rather than alarmist: PRP, fat grafting, and exosome therapies offer real aesthetic benefit when used with stewardship, but providers must understand each modality’s mechanism, screen patients for cardiovascular, hematological, and immunological risk factors, and prepare for the rare but catastrophic complications that these otherwise promising biologics can produce.

Subject of Research: Complications of regenerative medicine therapies, including platelet-rich plasma, fat and nanofat grafting, and exosomes, in facial plastic surgery

Article Title: Complications of regenerative therapeutics in facial plastic surgery: a case series and review of the literature

Article References: Green, K., Pascal, G. J., Tolaymat, L., Bruce, A., & Menapace, D. (2026). Complications of regenerative therapeutics in facial plastic surgery: a case series and review of the literature. BMC Plastic and Reconstructive Surgery, 2(1), Article 19. https://doi.org/10.1186/s44452-026-00032-w

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00032-w

Keywords: regenerative medicine, facial plastic surgery, platelet-rich plasma, fat grafting, nanofat, exosomes, blindness, embolism, aesthetic medicine, complications, PRP, cosmetic injections